PMC2779324_01
Clinical course of patient number 3.
jkms-20-947-g001.jpg
PMC2779324_01_jkms-20-947-g001.jpg
F1
A decrease in drainage was observed at an average of 3.1 days after the initiation of somatostatin, as the dose of somatostatin had increased enough to produce an effect (Fig. 1).
Clinical course of patient number 6.
jkms-20-947-g002.jpg
PMC2779324_01_jkms-20-947-g002.jpg
F2
In patient 6 and patient 9, a rebound phenomenon of chylothorax was noted upon the reduction of somatostatin therapy, but the rebound effusion responded promptly when the dose of somatostatin was boosted (Fig. 2).
PMC2779324_02
Clinical course of patient number 4.
jkms-20-947-g003.jpg
PMC2779324_02_jkms-20-947-g003.jpg
F3
In this patient, superior vena cava syndrome was considered a contributing factor for the prolonged chylous drainage, but the high dose somatostatin infusion was tolerated for 21 days without any apparent side effects (Fig. 3).
PMC2779324_03